MPZL3 and neoplasm: Although the effects in vivo are subtle, comparing tumor growth rates in response to cisplatin treatment, the scr control group significantly decreased their growth rate in response to cisplatin treatment, whereas a significant change was not observed following MPZL3 knockdown (Fig. 6E).